A clinical-level review of bisphosphonate drug-drug interactions, pharmacokinetics, dosing rules, and prescribing guidance for alendronate, zoledronic acid, risedronate, ibandronate, and pamidronate, with a full DDI table and primary-source citations.
A prescriber-level guide to copper peptide drug class pharmacology, compounding regulations, billing codes, and prior-authorization strategy for GHK-Cu and related peptides.
A clinical-level review of copper peptide pharmacology, dosing, and safety across special populations including pregnancy, pediatrics, renal impairment, and older adults. Written for prescribers and dispensing clinicians.
A prescriber-level guide to recognizing, grading, and managing adverse events from systemic estrogen therapy, covering VTE, endometrial risk, cardiovascular effects, and monitoring protocols with evidence from WHI, PEPI, and current NAMS/ACOG guidelines.
A prescriber-level monograph on systemic estrogens: pharmacology, formulations, dosing, indications, contraindications, monitoring, and key trial data for menopausal HRT and beyond.
A prescriber-level review of cholesterol absorption inhibitors, focusing on ezetimibe and emerging agents, with evidence-based guidance on when and how to add them to statin or non-statin regimens.
A board-reviewed prescriber guide to the GHRH analog drug class covering sermorelin, tesamorelin, and CJC-1295. Includes baseline labs, on-therapy monitoring intervals, dose-adjustment criteria, and safety thresholds with primary-source citations.
A clinical guide to GHRH analog selection, sermorelin, tesamorelin, CJC-1295, and modified peptides, covering pharmacology, dosing, indications, and how to choose between agents for GH axis stimulation.
A prescriber-level guide to managing adverse events with triple receptor agonists (GLP-1/GIP/glucagon), including retatrutide. Covers GI toxicity, cardiovascular monitoring, hepatic considerations, and dose-titration protocols grounded in Phase 2/3 trial data.
A prescriber-level guide to titrating and tapering retatrutide and other GLP-1/GIP/glucagon triple agonists, including dose schedules, stopping rules, and restart protocols based on current trial data.
GI side effects hit 30-50% of GLP-1 users and cause most early stops. See dose escalation, stopping rules, and pancreatitis risk factors to keep patients on therapy.
A clinical guide to selecting among GLP-1 receptor agonists, semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, based on weight, CV risk, renal function, dosing frequency, and cost. Written for prescribers and clinical pharmacists.
A prescriber-level guide to identifying, grading, and managing adverse events associated with GH secretagogue therapy, including ipamorelin, sermorelin, CJC-1295, and MK-677. Covers mechanism-based toxicity, monitoring schedules, and dose-adjustment algorithms.
A physician-level guide to monitoring patients on GH secretagogues (ipamorelin, CJC-1295, MK-677, GHRP-2, GHRP-6). Covers baseline labs, on-therapy intervals, dose titration, safety signals, and discontinuation criteria with primary-source citations.
Edema, paresthesia, and insulin resistance risk vary by age, sex, and comorbidity with GH secretagogues; see population-specific dosing and monitoring guidance.
A prescriber-level guide to BPC-157 and TB-500 dosing, titration schedules, tapering protocols, and the clinical rationale behind each step, with primary-source citations throughout.
A prescriber-level guide to basal insulin analog titration and tapering algorithms for T1D and T2D, including starting doses, adjustment protocols, and deprescribing strategies backed by clinical trial data.
Basaglar (glargine U-100) and Toujeo (glargine U-300) differ in concentration, duration, and hypoglycemia risk. Compare profiles to pick the right agent.
A clinician-level guide to preventing, recognizing, and managing adverse events with rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart, inhaled insulin). Includes hypoglycemia protocols, injection-site reactions, and dosing frameworks.
A prescriber-level review of rapid-acting insulin analogs (lispro, aspart, glulisine, ultra-rapid formulations) across pediatric, pregnant, elderly, and renal/hepatic-impaired populations, with dosing guidance and key trial data.
A clinical guide to choosing among lispro, aspart, glulisine, faster aspart, and ultra-rapid lispro for prandial insulin coverage. Written at MD/PharmD level with head-to-head trial data, dosing nuances, and practical switching guidance.
A clinical-level review of meglitinide adverse events, prescribing protocols, hypoglycemia management, drug interactions, and patient selection for repaglinide and nateglinide.
A clinical-level review of the meglitinides drug class covering repaglinide and nateglinide dosing, blood glucose monitoring targets, hypoglycemia management, renal and hepatic dose adjustments, drug interactions, and lab surveillance for prescribers and pharmacists.
A prescriber-level guide to melanocortin receptor agonists, bremelanotide, setmelanotide, afamelanotide, and investigational agents, covering mechanism, approved indications, dosing, and how to pick the right drug for each patient.
A practical, MD/PharmD-level guide to billing codes, prior-authorization strategies, and prescribing essentials for NAD precursor therapies including NMN, NR, and IV NAD+.
A prescriber-level guide to choosing between evolocumab, alirocumab, and inclisiran for FH, post-ACS, and statin-intolerant patients. Covers mechanism, dosing, trial data, payer hurdles, and a practical selection framework.
A board-reviewed, prescriber-level summary of PDE5 inhibitors across special populations including renal impairment, hepatic dysfunction, cardiovascular disease, older adults, and women, with dosing tables and guideline citations.
A prescriber-level guide to managing adverse events from micronized progesterone and synthetic progestins, covering class differences, dose adjustments, and evidence-based switching protocols for HRT and luteal support.
A clinical reference for prescribers and pharmacists on managing adverse events from RANK-L inhibitors (denosumab), including hypocalcemia, ONJ, atypical fractures, and rebound risk.
A clinical-grade guide to RANKL inhibitor billing, prior authorization, J-code submission, step-therapy requirements, and prescribing pearls for denosumab (Prolia/Xgeva) and emerging agents.
A physician- and pharmacist-level reference covering the RANKL inhibitor drug class, denosumab DDI table, dosing, monitoring, and clinical guidelines with primary-source citations.
A prescriber-level review of RANK-L inhibitors (denosumab, denosumab-prlia, and biosimilars), covering mechanism, approved indications, dosing, switching strategy, and how to choose between agents for osteoporosis and bone metastases.
A clinician-level guide to managing adverse events from selective estrogen receptor modulators (SERMs), including tamoxifen, raloxifene, clomiphene, and enclomiphene. Covers mechanism, class-specific toxicities, and evidence-based mitigation strategies.
A prescriber-level DDI reference for siRNA lipid therapeutics (inclisiran, vutrisiran, patisiran). Covers mechanism, pharmacokinetics, DDI table, dosing, and monitoring guidance with primary literature citations.
A clinical-level guide to recognizing, preventing, and managing adverse events from sulfonylurea therapy, including hypoglycemia protocols, weight gain strategies, and special-population dosing. Written for prescribers and pharmacists.
A prescriber- and pharmacist-level guide to sulfonylurea drug class pharmacology, formulary positioning, billing codes, and prior-authorization strategy for T2D management.
A board-reviewed, MD/PharmD-level guide to the sulfonylureas monitoring bundle covering baseline labs, hypoglycemia protocols, renal and hepatic dose adjustments, cardiovascular safety, and drug interactions for glipizide, glyburide, and glimepiride.
A clinical-level review of sulfonylurea pharmacology, dosing, and special-population considerations for prescribers and pharmacists managing T2D.
A detailed guide to BCBS Texas Vyvanse coverage, prior authorization requirements, formulary tiers, cost-saving strategies, and what to do if your claim is denied.
A guide to ADHD stimulant titration covering methylphenidate and amphetamine dose escalation schedules, switching protocols, modafinil dosing, and how to recognize an optimal dose.
Adderall can trigger panic attacks by raising norepinephrine and dopamine, especially above 20mg. Symptoms often start within 1-2 hours of dosing.
Cold plunge and cognition: a breakdown of the norepinephrine response, relevant human trials, and how cold-water immersion compares to stimulant medications for focus and mental clarity.
A guide to donepezil (Aricept) and how it compares with modafinil, armodafinil, methylphenidate (Ritalin/Concerta), and amphetamines (Adderall) for cognitive performance, memory, and mental clarity.
On an empty stomach, Vyvanse kicks in about 1.5 to 2 hours after a dose, peaks near 3.8 hours, and lasts 10 to 14 hours. A high-fat meal delays it 1 hour.
A guide to memantine (Namenda): how the NMDA antagonist works, approved doses, real clinical-trial outcomes, and how it fits alongside stimulants like modafinil, methylphenidate, and amphetamine salts.
A guide to modafinil standard dosing covering approved doses, titration schedules, timing, off-label cognitive use, and how to switch from other wakefulness agents.
Phenibut withdrawal can produce severe anxiety, insomnia, and psychosis-like symptoms lasting weeks. Learn the real timeline, risk factors, medical detox options, and what clinicians recommend for tapering safely.
Mixing phenibut and Adderall can mask overdose signs and strain the heart. See how phenibut works, its dependence risk, and safer alternatives.
Strattera works slower (4-8 weeks) with a smaller effect size (d~0.6-0.7) than stimulants (d~0.9, 30-60 min onset), but carries no abuse risk.
Evolocumab (Repatha) lowers LDL-C by 59% while losartan reduces blood pressure and protects the kidneys. Learn why cardiologists often prescribe both, how they interact, and when combining them makes clinical sense.
Ezetimibe (Zetia) lowers LDL-C; amlodipine lowers blood pressure. They work through completely different mechanisms, which is exactly why cardiologists often prescribe both at once. This guide explains the science, the evidence, and the real risks of combining them.
Inclisiran lowers LDL-C about 50% with two shots yearly; ezetimibe cuts it 18-20% orally with proven MACE reduction. Compare safety and switching.
Losartan lowers albuminuria, favoring kidney protection in diabetes or CKD; amlodipine lowers BP more. Both cost under $15/month generic.
A detailed clinical comparison of losartan and amlodipine for hypertension, including how to switch between them safely, trial data from LIFE and ASCOT-BPLA, and guidance on which drug fits which patient profile.
A clinical comparison of modafinil (Provigil) and lisdexamfetamine (Vyvanse) for cognition and mental performance, covering mechanism, trial data, dosing, side effects, and which patients each drug suits best.
A comparison of modafinil (Provigil) and lisdexamfetamine (Vyvanse) covering mechanism, efficacy data, side-effect profiles, and a step-by-step guide to switching between them.
A detailed clinical comparison of semaglutide (Ozempic) and liraglutide side-effect profiles, using SUSTAIN-7, SCALE Obesity, and FDA labeling data to help patients and clinicians choose between these two GLP-1 receptor agonists.
A rigorous comparison of semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) for weight loss, drawing on STEP-1, SURMOUNT-1, and the first direct head-to-head trial data available.
Zepbound and Mounjaro both contain tirzepatide, but they carry different FDA approvals, pricing structures, and titration targets. This guide explains what changes and what stays the same when you switch between them.
A detailed clinical comparison of dapagliflozin (Farxiga) and metformin side-effect profiles, including cardiovascular outcomes, GI tolerability, and prescribing guidance from named trials and guidelines.